EpiBiologics Secures $107M Series B, Propelling Precision Protein Degradation for Cancer and Immunity
January 11, 2026, 9:36 am
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Founded date: 2015
Johnson & Johnson Innovation - JJDC
Employees: 11-50
EpiBiologics closed a $107 million Series B. This investment accelerates its EpiTAC platform. The platform develops tissue-selective extracellular protein degraders. These target disease-driving membrane and soluble proteins. Lead candidate EPI-326 is an EGFR degrader. It shows promise for non-small cell lung cancer and head and neck squamous cell carcinoma. Clinical trials begin early 2026. The funding expands oncology and immunology pipelines. GV and Johnson & Johnson co-led the round. New investors joined existing ones. Leadership and board expanded. This strengthens EpiBiologics' path to market. It addresses critical patient needs with novel therapies.
EpiBiologics achieved a significant milestone. The San Mateo, California company closed a $107 million Series B financing round. This substantial investment fuels its innovative EpiTAC platform. It advances a pipeline of next-generation bispecific antibodies. These therapies target extracellular protein degradation. The focus spans both oncology and immunology. The company aims to redefine treatment paradigms.
The Series B round demonstrated strong investor confidence. GV and Johnson & Johnson co-led the financing. Johnson & Johnson joined through its innovation arm, JJDC. Prominent new investors also participated. These included Novartis Venture Fund, Aulis Capital, Avego BioScience Capital, and Samsara BioCapital. Existing backers reaffirmed their commitment. Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital continued their support. This diverse consortium underscores the potential of EpiBiologics’ groundbreaking approach.
At the core of EpiBiologics’ strategy is the EpiTAC platform. This proprietary technology employs a modular bispecific antibody system. It drives targeted degradation of specific proteins. These proteins are often critical for disease progression. The platform focuses specifically on extracellular membrane and soluble proteins. Its unique strength lies in tissue-selectivity. This precision aims to localize therapeutic effect. It minimizes off-target activity. Such selectivity is vital for improved safety and enhanced efficacy in new treatments.
The lead program is EPI-326. This candidate is a tissue-selective bispecific antibody. It targets oncogenic forms of EGFR. EGFR mutations drive many aggressive cancers. EPI-326 offers a mutation-agnostic approach. This broad utility is a key advantage. Preclinical studies have yielded compelling data. They show durable efficacy across various models. The safety profile appears favorable. Pharmacokinetics also support its development. EPI-326 shows promise as both a monotherapy and in combination strategies. It addresses multiple cancer types, offering flexible treatment options.
EpiBiologics plans swift clinical translation for EPI-326. A first-in-human clinical trial is slated for early 2026. This trial will target non-small cell lung cancer (NSCLC). It will also include head and neck squamous cell carcinoma (HNSCC). These cancers represent areas of significant unmet medical need. Current therapies often face resistance or toxicity challenges. EPI-326 seeks to overcome these hurdles. Its precise mechanism offers new hope for patients.
Beyond EPI-326, EpiBiologics maintains a robust pipeline. The EpiTAC platform supports development of additional bispecific antibodies. These are designed for various oncology indications. They also extend into immunology applications. The company envisions a broad impact across multiple debilitating diseases. Protein degradation represents a cutting-edge frontier in drug discovery. EpiBiologics stands at its forefront for extracellular targets. This innovation expands the druggable proteome significantly.
The company also bolstered its leadership team and board. Eric Humke joined as Chief Medical Officer in 2025. Aaron Mishel assumed the role of Chief Financial Officer. These appointments bring deep industry expertise. They strengthen EpiBiologics’ operational and clinical development capabilities. Their experience will guide the company through critical growth phases.
The board of directors saw significant expansion. Anika Gupta Vatsa from GV joined. Laura Brass from Novartis Venture Fund also became a new member. Gaurav Aggarwal from Vivo Capital added his insights. A representative from JJDC further solidified the board. Board observers were also appointed. Nisa Leung from Aulis, Eric Pham from Avego, and Mitchell Mutz from Samsara will contribute. This expanded governance provides strategic oversight. It supports the company’s ambitious growth plans for its diverse pipeline.
EpiBiologics’ approach holds immense potential. Protein degradation therapies are transforming medicine. Most current degraders target intracellular proteins. EpiBiologics extends this powerful modality to extracellular and membrane-bound targets. This opens entirely new therapeutic avenues. It allows addressing proteins previously considered "undruggable." The tissue-selective design promises better patient outcomes. It offers reduced systemic side effects. This precision medicine approach aligns with modern therapeutic goals.
The biopharmaceutical market keenly observes this space. Investment in innovative oncology and immunology platforms remains strong. EpiBiologics’ successful Series B reflects this trend. It validates their scientific rigor and commercial promise. The company is poised for substantial progress. Its unique platform differentiates it in a competitive landscape. It offers a powerful new tool in the fight against complex diseases. This funding enables further research and development. It accelerates the journey from lab to clinic. Patients worldwide await these breakthroughs. EpiBiologics is committed to delivering them. Its trajectory suggests a significant future impact on global health.
EpiBiologics achieved a significant milestone. The San Mateo, California company closed a $107 million Series B financing round. This substantial investment fuels its innovative EpiTAC platform. It advances a pipeline of next-generation bispecific antibodies. These therapies target extracellular protein degradation. The focus spans both oncology and immunology. The company aims to redefine treatment paradigms.
The Series B round demonstrated strong investor confidence. GV and Johnson & Johnson co-led the financing. Johnson & Johnson joined through its innovation arm, JJDC. Prominent new investors also participated. These included Novartis Venture Fund, Aulis Capital, Avego BioScience Capital, and Samsara BioCapital. Existing backers reaffirmed their commitment. Polaris Partners, Digitalis Ventures, Taiho Ventures, Vivo Capital, Codon Capital, and Mission BioCapital continued their support. This diverse consortium underscores the potential of EpiBiologics’ groundbreaking approach.
At the core of EpiBiologics’ strategy is the EpiTAC platform. This proprietary technology employs a modular bispecific antibody system. It drives targeted degradation of specific proteins. These proteins are often critical for disease progression. The platform focuses specifically on extracellular membrane and soluble proteins. Its unique strength lies in tissue-selectivity. This precision aims to localize therapeutic effect. It minimizes off-target activity. Such selectivity is vital for improved safety and enhanced efficacy in new treatments.
The lead program is EPI-326. This candidate is a tissue-selective bispecific antibody. It targets oncogenic forms of EGFR. EGFR mutations drive many aggressive cancers. EPI-326 offers a mutation-agnostic approach. This broad utility is a key advantage. Preclinical studies have yielded compelling data. They show durable efficacy across various models. The safety profile appears favorable. Pharmacokinetics also support its development. EPI-326 shows promise as both a monotherapy and in combination strategies. It addresses multiple cancer types, offering flexible treatment options.
EpiBiologics plans swift clinical translation for EPI-326. A first-in-human clinical trial is slated for early 2026. This trial will target non-small cell lung cancer (NSCLC). It will also include head and neck squamous cell carcinoma (HNSCC). These cancers represent areas of significant unmet medical need. Current therapies often face resistance or toxicity challenges. EPI-326 seeks to overcome these hurdles. Its precise mechanism offers new hope for patients.
Beyond EPI-326, EpiBiologics maintains a robust pipeline. The EpiTAC platform supports development of additional bispecific antibodies. These are designed for various oncology indications. They also extend into immunology applications. The company envisions a broad impact across multiple debilitating diseases. Protein degradation represents a cutting-edge frontier in drug discovery. EpiBiologics stands at its forefront for extracellular targets. This innovation expands the druggable proteome significantly.
The company also bolstered its leadership team and board. Eric Humke joined as Chief Medical Officer in 2025. Aaron Mishel assumed the role of Chief Financial Officer. These appointments bring deep industry expertise. They strengthen EpiBiologics’ operational and clinical development capabilities. Their experience will guide the company through critical growth phases.
The board of directors saw significant expansion. Anika Gupta Vatsa from GV joined. Laura Brass from Novartis Venture Fund also became a new member. Gaurav Aggarwal from Vivo Capital added his insights. A representative from JJDC further solidified the board. Board observers were also appointed. Nisa Leung from Aulis, Eric Pham from Avego, and Mitchell Mutz from Samsara will contribute. This expanded governance provides strategic oversight. It supports the company’s ambitious growth plans for its diverse pipeline.
EpiBiologics’ approach holds immense potential. Protein degradation therapies are transforming medicine. Most current degraders target intracellular proteins. EpiBiologics extends this powerful modality to extracellular and membrane-bound targets. This opens entirely new therapeutic avenues. It allows addressing proteins previously considered "undruggable." The tissue-selective design promises better patient outcomes. It offers reduced systemic side effects. This precision medicine approach aligns with modern therapeutic goals.
The biopharmaceutical market keenly observes this space. Investment in innovative oncology and immunology platforms remains strong. EpiBiologics’ successful Series B reflects this trend. It validates their scientific rigor and commercial promise. The company is poised for substantial progress. Its unique platform differentiates it in a competitive landscape. It offers a powerful new tool in the fight against complex diseases. This funding enables further research and development. It accelerates the journey from lab to clinic. Patients worldwide await these breakthroughs. EpiBiologics is committed to delivering them. Its trajectory suggests a significant future impact on global health.